Page 1 | Search Results | Blood | American Society of Hematology

1-18 of 18

Sort by

Sort Order Select

Journal Articles

Impact of Minimal Residual Disease in Transplant Ineligible Myeloma Patients: Results from the UK NCRI Myeloma XI Trial

Ruth Mary de Tute, PhD FRCPath, Andy C Rawstron, BSc, PhD, David A Cairns, MSc, PhD, Charlotte Pawlyn, MB BChir, Faith E Davies, MD, Corinne Collett, Martin F Kaiser, John R Jones, MD, Anna Waterhouse, Alina Striha, MSc, Gordon Cook, MDPhD, Matthew W Jenner, MD, Nigel H Russell, MD, Mark T Drayson, MD PhD, Walter M Gregory, PhD, Graham H Jackson, MD PhD, Gareth J Morgan, MD PhD, Roger G Owen, MD

Blood (2016) 128 (22): 245.

https://doi.org/10.1182/blood.V128.22.245.245

Published: 2016

Journal Articles

Lenalidomide Is a Highly Effective Maintenance Therapy in Myeloma Patients of All Ages; Results of the Phase III Myeloma XI Study

Blood (2016) 128 (22): 1143.

https://doi.org/10.1182/blood.V128.22.1143.1143

Published: 2016

Journal Articles

Primary IMiD Refractory Myeloma; Results from 3894 Patients Treated in the Phase III Myeloma XI Study

Blood (2016) 128 (22): 1144.

https://doi.org/10.1182/blood.V128.22.1144.1144

Published: 2016

Journal Articles

Multiple Myeloma with a Deletion of Chromosome 17p: TP53 Mutations Are Highly Prevalent and Negatively Affect Prognosis

Blood (2016) 128 (22): 3271.

https://doi.org/10.1182/blood.V128.22.3271.3271

Published: 2016

Journal Articles

Inhibition of the Epigenetic Modifier EZH2 Upregulates Cell Cycle Control Genes to Inhibit Myeloma Cell Growth and Overcome High-Risk Disease Features

Charlotte Pawlyn, MB BChir, Michael Bright, PhD, Amy Buros, PhD, Caleb K. Stein, MS, Zoe Walters, PhD, Lauren Aronson, PhD, Fabio Mirabella, PhD, Martin F Kaiser, MD, John R Jones, MD, Brian A Walker, PhD, Graham H Jackson, MD PhD, Paul Clarke, PhD, Leif Bergsagel, MD, Paul Workman, PhD, Marta Chesi, PhD, Gareth J Morgan, MD PhD, Faith E Davies, MD

Blood (2016) 128 (22): 3289.

https://doi.org/10.1182/blood.V128.22.3289.3289

Published: 2016

Journal Articles

Response Adapted Induction Treatment Improves Outcomes for Myeloma Patients; Results of the Phase III Myeloma XI Study

Blood (2016) 128 (22): 244.

https://doi.org/10.1182/blood.V128.22.244.244

Published: 2016

Journal Articles

DNA Methylation Profiling of Myeloma Trial Patients Reveals Specific Epigenetic Changes Associated with Outcome

Blood (2016) 128 (22): 804.

https://doi.org/10.1182/blood.V128.22.804.804

Published: 2016

Journal Articles

The Impact of Maintenance Lenalidomide on the Mutational Status of the Myeloma Clone at Relapse in the NCRI Myeloma XI Trial for Newly Diagnosed Multiple Myeloma Patients (NDMM)

Blood (2016) 128 (22): 4412.

https://doi.org/10.1182/blood.V128.22.4412.4412

Published: 2016

Journal Articles

The Multiple Myeloma Genome Project: Development of a Molecular Segmentation Strategy for the Clinical Classification of Multiple Myeloma

Brian A Walker, PhD, Mehmet K. Samur, PhD, Konstantinos Mavrommatis, Cody Ashby, PhD, Christopher P Wardell, PhD, Maria Ortiz, PhD, Fadi Towfic, Caleb K. Stein, MS, Michael A Bauer, PhD, Michael Amatangelo, PhD, Giovanni Parmigiani, PhD, Zhinuan Yu, PhD, Matthew Trotter, Herve Avet-Loiseau, MD PhD, Graham H Jackson, MD PhD, Kenneth C. Anderson, Anjan Thakurta, PhD, Nikhil C. Munshi, MD, Gareth J Morgan, MD PhD

Blood (2016) 128 (22): 196.

https://doi.org/10.1182/blood.V128.22.196.196

Published: 2016

Journal Articles

Identifying Ultra-High Risk Myeloma By Integrated Molecular Genetic and Gene Expression Profiling

Blood (2016) 128 (22): 4407.

https://doi.org/10.1182/blood.V128.22.4407.4407

Published: 2016

Journal Articles

Molecular Subtyping and Risk Stratification for the Classification of Myeloma

Caleb K. Stein, MS, Faith E Davies, MD, Christoph Heuck, MD, Niels Weinhold, PhD, Shweta S. Chavan, PhD, Brian A Walker, PhD, Sharmilan Thanendrarajan, MD, Joshua Epstein, DSc, Shmuel Yaccoby, PhD, Maurizio Zangari, MD, Frits van Rhee, MD PhD, Martin F Kaiser, MD, Graham H Jackson, MD PhD, Pieter Sonneveld, MD PhD, Hartmut Goldschmidt, MD, Peter Leif Bergsagel, MD, Bart Barlogie, MD PhD, Gareth J Morgan, MDPhD

Blood (2015) 126 (23): 4173.

https://doi.org/10.1182/blood.V126.23.4173.4173

Published: 2015

Journal Articles

Spatiotemporal Analysis of Intraclonal Heterogeneity in Multiple Myeloma: Unravelling the Impact of Treatment and the Propagating Capacity of Subclones Using Whole Exome Sequencing

Blood (2015) 126 (23): 371.

https://doi.org/10.1182/blood.V126.23.371.371

Published: 2015

Journal Articles

Mutational Patterns and Copy Number Changes at Diagnosis Are a Powerful Tool to Predict Outcome: Result of the Sequencing Study of 463 Newly Diagnosed Myeloma Trial Patients

Blood (2014) 124 (21): 637.

https://doi.org/10.1182/blood.V124.21.637.637

Published: 2014

Journal Articles

The Extent of Intra-Clonal Genetic Diversity within the Myeloma Clone Is a Predictive Biomarker of Progression and Outcome after Treatment

Blood (2014) 124 (21): 640.

https://doi.org/10.1182/blood.V124.21.640.640

Published: 2014

Journal Articles

Synergy of Unrelated Donor and Full Intensity Conditioning Breaks the Control of Graft Versus Host Disease By Alemtuzumab

Olivia Laverick, BSc, Amy Publicover, MD, Laura Jardine, MD, Kile Green, BSc, Alan Potter, BSc, Graham H Jackson, MD PhD, Matthew Collin, MD PhD

Blood (2014) 124 (21): 1206.

https://doi.org/10.1182/blood.V124.21.1206.1206

Published: 2014

Journal Articles

The Interaction of Response and FISH-Based Risk Stratification to Better Define Clinical Outcome in Myeloma

Kevin D Boyd, MD, Fiona M Ross, DPhil, Mark T Drayson, MD, Roger G Owen, MD, Alex J Szubert, MSc, Walter M Gregory, PhD, Christopher P Wardell, PhD, Faith E Davies, MD, Graham H Jackson, MD, PhD, J. Anthony Child, MD, Gareth J Morgan, MD PhD

Blood (2011) 118 (21): 1823.

https://doi.org/10.1182/blood.V118.21.1823.1823

Published: 2011

Journal Articles

Reduced Intensity Hematopoietic Stem Cell Transplant Rescues Immune Function and Corrects Pulmonary Alveolar Proteinosis in DCML Deficiency/GATA 2 Mutation

Blood (2011) 118 (21): 2045.

https://doi.org/10.1182/blood.V118.21.2045.2045

Published: 2011

Journal Articles

A Retrospective Study of Alemtuzumab Level, T Cell Chimerism and Graft Versus Host Disease Using Intermediate Dose Alemtuzumab for Matched Related and Matched Unrelated Reduced Intensity Transplantation.

Andrew Charlton, MD, Laura Spence, MD, Venetia Bigley, MD, Natasha Groves, PhD, Geoff Hale, PhD, Sarah Pagan, BSc, Brie E Turner, PhD, Gail Jones, MD, PhD, Graham H Jackson, MD, PhD, Anne M Dickinson, PhD, Matthew Collin, MD, PhD

Blood (2009) 114 (22): 3333.

https://doi.org/10.1182/blood.V114.22.3333.3333

Published: 2009

NARROW

Impact of Minimal Residual Disease in Transplant Ineligible Myeloma Patients: Results from the UK NCRI Myeloma XI Trial

Lenalidomide Is a Highly Effective Maintenance Therapy in Myeloma Patients of All Ages; Results of the Phase III Myeloma XI Study

Primary IMiD Refractory Myeloma; Results from 3894 Patients Treated in the Phase III Myeloma XI Study

Multiple Myeloma with a Deletion of Chromosome 17p: TP53 Mutations Are Highly Prevalent and Negatively Affect Prognosis

Inhibition of the Epigenetic Modifier EZH2 Upregulates Cell Cycle Control Genes to Inhibit Myeloma Cell Growth and Overcome High-Risk Disease Features

Response Adapted Induction Treatment Improves Outcomes for Myeloma Patients; Results of the Phase III Myeloma XI Study

DNA Methylation Profiling of Myeloma Trial Patients Reveals Specific Epigenetic Changes Associated with Outcome

The Impact of Maintenance Lenalidomide on the Mutational Status of the Myeloma Clone at Relapse in the NCRI Myeloma XI Trial for Newly Diagnosed Multiple Myeloma Patients (NDMM)

The Multiple Myeloma Genome Project: Development of a Molecular Segmentation Strategy for the Clinical Classification of Multiple Myeloma

Identifying Ultra-High Risk Myeloma By Integrated Molecular Genetic and Gene Expression Profiling

Molecular Subtyping and Risk Stratification for the Classification of Myeloma

Spatiotemporal Analysis of Intraclonal Heterogeneity in Multiple Myeloma: Unravelling the Impact of Treatment and the Propagating Capacity of Subclones Using Whole Exome Sequencing

Mutational Patterns and Copy Number Changes at Diagnosis Are a Powerful Tool to Predict Outcome: Result of the Sequencing Study of 463 Newly Diagnosed Myeloma Trial Patients

The Extent of Intra-Clonal Genetic Diversity within the Myeloma Clone Is a Predictive Biomarker of Progression and Outcome after Treatment

Synergy of Unrelated Donor and Full Intensity Conditioning Breaks the Control of Graft Versus Host Disease By Alemtuzumab

The Interaction of Response and FISH-Based Risk Stratification to Better Define Clinical Outcome in Myeloma

Reduced Intensity Hematopoietic Stem Cell Transplant Rescues Immune Function and Corrects Pulmonary Alveolar Proteinosis in DCML Deficiency/GATA 2 Mutation

A Retrospective Study of Alemtuzumab Level, T Cell Chimerism and Graft Versus Host Disease Using Intermediate Dose Alemtuzumab for Matched Related and Matched Unrelated Reduced Intensity Transplantation.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only